Detection method of Jinli oil soft capsule
Through network pharmacological analysis and high-performance liquid chromatography detection, 10 pharmaceutically active ingredients in Jinliyou soft capsules are identified and determined, which solves the problem of incomplete existing detection methods, provides reliable quality control measures, and ensures the product consistency and effectiveness.
Patent Information
- Application Number
- CN202411013778.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The types and content detection methods of the existing Jinli Oil Soft Capsules are not comprehensive and are difficult to serve as an accurate indicator of quality control.
The 10 pharmacological active ingredients of Jinli Oil soft capsules were determined by network pharmacological analysis methods, and the mass content of these ingredients was obtained by high performance liquid chromatography detection, providing gradient elution procedures and linear regression equations to ensure accurate determination.
It realizes accurate identification of the types of active ingredients of traditional Chinese medicine and efficient detection of the content of Jinli Oil Soft Capsules, provides reliable quality control indicators, and ensures the consistency and effectiveness of the product.
Smart Images

Figure CN118937551A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug analysis, and particularly relates to a method for detecting Jinliyou soft capsules. Background Art
[0002] Benign prostatic hyperplasia (BPH) is a common urological disease that causes urination disorders in middle-aged and elderly men. Statistics show that the incidence of BPH in men aged 60 is greater than 50%, and it reaches more than 80% at the age of 80. BPH is mainly manifested by histological hyperplasia of prostate stroma and glandular components, anatomical enlargement of the prostate, urodynamic bladder outlet obstruction and lower urinary tract symptoms (LUTS). The disease is characterized by frequent urination, urgency, and frequent urination at night, which seriously affects the patient's sleep quality and daily activities. Regarding the pathogenesis of BPH, there are several hypotheses in the discipline: autoimmune inflammation, urothelial integrity and functional defects, occult prostate infection, urination dysfunction, pelvic floor muscle spasm / pain, neuroendocrine disorders, peripheral / central nervous sensitization, neural remodeling, social and psychological conditions and genetic factors. Some researchers have also proposed that prostate microenvironment disorder, that is, local prostate microenvironment disorder caused by the combined effects of immune disorders, oxidative stress (OS), and pain factor release may be an important pathogenesis of BPH.
[0003] At present, the main treatments for BPH patients are surgical resection and drug therapy. Among them, surgical treatments include bipolar urethral plasma resection of the prostate (TUPKP) and urethral plasma enucleation of the prostate (TUKEP). Both surgical treatments have postoperative complications: urinary incontinence is about 1-2.2%, retrograde ejaculation is about 65-70%, and urethral stenosis is about 3.8%. Commonly used Western medicines for the treatment of BPH are α1-receptor blockers and 5α-reductase inhibitors. Among them, α1-receptor blockers are suitable for patients with prostatic hyperplasia with moderate to severe lower urinary tract symptoms. Commonly used drugs are: doxazosin, terazosin, and tamsulosin. 5α-reductase is a reductase that converts testosterone to dihydrotestosterone. Dihydrotestosterone has a certain role in benign prostatic hyperplasia. The use of 5α-reductase inhibitors can inhibit hyperplasia to a certain extent. Commonly used drugs are: finasteride and dutasteride. Common side effects of long-term use of this type of drug include dizziness, headache, fatigue, drowsiness, postural hypotension, abnormal ejaculation, etc. In view of the limitations of surgery itself and the serious side effects of existing drug treatments, Chinese patent medicines have become the preferred way to treat BPH.
[0004] Traditional Chinese medicine believes that this disease belongs to the category of "spermia", "urinary retention" and "stranguria syndrome". There are many records of stranguria in ancient Chinese medicine books. "Suwen·Wuchang Zhengdalun" states: "The disease of stranguria is caused by evil damaging the kidney." "Lingshu Jing·Benshu" says: "The triple burner... if it is full, it will cause stranguria, and if it is empty, it will cause nocturnal emission." "Suwen·Xuanming Wuqi" records: "Urinary bladder dysfunction is stranguria, and nocturnal emission." "Suwen·Biaobenbingchuanlun" believes that "bladder disease leads to urinary retention" (Zhang Chunhe, 2016). Traditional Chinese medicine believes that the etiology and pathogenesis of BPH are closely related to factors such as kidney deficiency and weak qi, blood stasis, dampness and heat. Traditional Chinese medicine emphasizes syndrome differentiation and treatment, and the treatment should be to activate blood circulation and remove blood stasis, promote dampness and relieve stranguria, and tonify the kidney. Developing and finding convenient, effective and low-toxic Chinese patent medicines is an urgent task for the treatment of BPH.
[0005] Jinliyou soft capsule is a national new drug approved by the State Food and Drug Administration for the treatment of prostatic hyperplasia. Previous clinical studies of the drug have also confirmed this indication. Jinliyou soft capsule is composed of 10 Chinese medicines, including Radix Bupleuri, Linderae Radix, Glycyrrhiza Uralensis Fisch., Sesami Nigrum Semen., Coptis Rhizoma, Amygdalus Communis Vas, Ephedra Herba, Gentiana Macrophylla Pall, Fraxini Cortex, and Aconitum Kusnezoffii Reichb. Jinliyou soft capsule has a clear clinical efficacy in the treatment of prostatic hyperplasia, but its pharmacodynamic material basis, that is, the type of pharmacologically active ingredients of Jinliyou soft capsule is not clear, and the detection method of the active ingredient content in Jinliyou soft capsule is not comprehensive. Summary of the invention
[0006] The purpose of the present invention is to provide a detection method for Jinliyou soft capsules. The detection method provided by the present invention determines the type of pharmacologically active ingredients of Jinliyou soft capsules and provides a detection method for the content of pharmacologically active ingredients of Jinliyou soft capsules, which can be used as a quality control indicator of Jinliyou soft capsules.
[0007] In order to achieve the above object, the present invention provides the following technical solutions:
[0008] The present invention provides a method for detecting Jinliyou soft capsules, comprising the following steps:
[0009] According to the effective chemical components of the 10 traditional Chinese medicines constituting the Jinliyou soft capsule, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsule, 10 pharmacologically active ingredients of the Jinliyou soft capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, kaempferol, β-sitosterol, naringenin, isorhamnetin, stigmasterol, glabridin, licorice chalcone B, (+)-catechin and 7-methoxy-2-methyl soy isoflavones;
[0010] The Jinliyou soft capsule is extracted with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested;
[0011] Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested;
[0012] The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients;
[0013] The conditions for the high performance liquid chromatography detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is methanol; gradient elution is adopted, and the procedure of the gradient elution is:
[0014] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 94 6 8 80.4 19.6 14 71.4 28.6 20 60 40 22 60 40 23 94 6 .
[0015] Preferably, the conditions for the HPLC detection also include: a column temperature of 30°C, a flow rate of the mobile phase of 1 mL·min -1 .
[0016] Preferably, the conditions for the HPLC detection also include: a detection wavelength of 278 nm.
[0017] Preferably, the alcohol-water solvent for dissolving the sample to be tested is a methanol-water solution, and the mass percentage of methanol in the methanol-water solution is 80 wt %.
[0018] Preferably, in the liquid chromatography detection, the injection volume of the sample solution to be tested is 10 μL.
[0019] Preferably, the polar solvent used for the extraction is a low-carbon alcohol or a low-carbon alcohol aqueous solution, the low-carbon alcohol includes methanol or ethanol, and the low-carbon alcohol aqueous solution includes a methanol aqueous solution or an ethanol aqueous solution; the mass percentage of the low-carbon alcohol in the low-carbon alcohol aqueous solution is 80%.
[0020] Preferably, the solid-liquid ratio of the Jinliyou soft capsule to the polar solvent is 1:(15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions.
[0021] Preferably, the method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients comprises the following steps:
[0022] Dissolving 10 pharmacologically active ingredients and a marker in an alcohol-water solvent, respectively, wherein the marker comprises one or more of phenol, catechol and phloroglucinol, respectively obtaining a series of standard solutions of the 10 pharmacologically active ingredients and the marker at different mass concentrations, respectively subjecting the 10 pharmacologically active ingredients and the marker at a series of standard solutions at different mass concentrations to high performance liquid chromatography detection, respectively obtaining a series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and the marker, and obtaining liquid chromatographic retention times and linear ranges of the 10 pharmacologically active ingredients and the marker from the series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and the marker;
[0023] A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 10 pharmacologically active ingredients, a marker and an alcohol-water solvent, wherein the marker includes one or more of phenol, catechol and phloroglucinol; a linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions and the liquid chromatographic retention times of the 10 pharmacologically active ingredients is obtained;
[0024] The linear regression equations of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution.
[0025] Preferably, the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution includes:
[0026] The linear regression equation of the mass concentration and peak area of glabridin is shown in Formula 1:
[0027] y=1805.5x-11.356 Formula 1;
[0028] The linear regression equation of the mass concentration and peak area of the licorice chalcone B is shown in Formula 2:
[0029] y=27559x+5.3815Equation 2;
[0030] The linear regression equation of the mass concentration and peak area of the (+)-catechin is shown in Formula 3:
[0031] y=26758x+4.4018Equation 3;
[0032] The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 4:
[0033] y=1526.7x-5.9019 equation 4;
[0034] The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 5:
[0035] y=5903x-47.215 Formula 5;
[0036] The linear regression equation of the mass concentration and peak area of naringenin is shown in Formula 6:
[0037] y = 2902x - 20.741 Formula 6;
[0038] The linear regression equation of the mass concentration and peak area of isorhamnetin is shown in Formula 7:
[0039] y=11901x-364.91Equation 7;
[0040] The linear regression equation of the mass concentration and peak area of the 7-methoxy-2-methyl soy isoflavones is shown in Formula 8:
[0041] y=7113x-33.718 Formula 8;
[0042] The linear regression equation of the mass concentration and peak area of β-sitosterol is shown in Formula 9:
[0043] y = 12619x - 350.71 Formula 9;
[0044] The linear regression equation of the mass concentration and peak area of the stigmasterol is shown in Formula 10:
[0045] y = 18471x-608 formula 10;
[0046] In formulas 1 to 10, X represents the mass concentration of glabridin, the mass concentration of licorice chalcone B, the mass concentration of (+)-catechin, the mass concentration of quercetin, the mass concentration of kaempferol, the mass concentration of naringenin, the mass concentration of isorhamnetin, the mass concentration of 7-methoxy-2-methyl soy isoflavones, the mass concentration of β-sitosterol, and the mass concentration of stigmasterol in the mixed standard solution, respectively;
[0047] In Formulas 1 to 10, Y represents the peak area of glabridin, the peak area of licorice chalcone B, the peak area of (+)-catechin, the peak area of quercetin, the peak area of kaempferol, the peak area of naringenin, the peak area of isorhamnetin, the peak area of 7-methoxy-2-methyl soy isoflavones, the peak area of β-sitosterol, and the peak area of stigmasterol in the liquid chromatogram of the mixed standard solution, respectively.
[0048] Preferably, the chromatographic column used in the high performance liquid chromatography is a Poroshell 120EC-C18 chromatographic column; the length of the chromatographic column is 150 mm, the inner diameter is 4.6 mm, and the size of the filler is 4 μm.
[0049] The invention provides a detection method for Jinliyou soft capsules, comprising the following steps: according to the effective chemical components of 10 traditional Chinese medicines constituting the Jinliyou soft capsules, a network pharmacology analysis method is adopted to obtain a compound traditional Chinese medicine network pharmacology map of the Jinliyou soft capsules, and according to the compound traditional Chinese medicine network pharmacology map of the Jinliyou soft capsules, 10 pharmacologically active ingredients of the Jinliyou soft capsules are obtained, wherein the 10 pharmacologically active ingredients are quercetin, kaempferol, β-sitosterol, naringenin, isorhamnetin, stigmasterol, glabridin, licorice chalcone B, (+)-catechin and 7-methoxy-2-methyl soybean isoflavones; the Jinliyou soft capsules are extracted with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested; the The sample to be tested is dissolved in an alcohol-water solvent to obtain a sample solution to be tested; the sample solution to be tested is subjected to high performance liquid chromatography detection to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from the liquid chromatogram of the sample solution to be tested; the mass contents of the 10 pharmacologically active ingredients in the Jinliyou soft capsule are then obtained from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the 10 pharmacologically active ingredients; the conditions for the high performance liquid chromatography detection include: the mobile phase includes a mobile phase A and a mobile phase B, the mobile phase A is a 0.1 v:v% formic acid aqueous solution, and the mobile phase B is methanol; gradient elution is adopted, and the procedure of the gradient elution is as above. The detection method provided by the present invention adopts a network pharmacology analysis method to accurately determine 10 pharmacologically active ingredients of Jinliyou soft capsules, and provides a high performance liquid chromatography detection method for the content of pharmacologically active ingredients of Jinliyou soft capsules. By controlling the detection conditions of the high performance liquid chromatography, the 10 pharmacologically active ingredients of Jinliyou soft capsules can be accurately obtained, thereby being used as quality control indicators of Jinliyou soft capsules. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] Figure 1 This is the network pharmacology diagram of the compound Chinese medicine Jinliyou soft capsule. Figure 1 The squares are Chinese medicinal materials, the circles are ingredients, the diamonds are targets, and the hexagons are common ingredients;
[0051] Figure 2 is the liquid chromatogram of the mixed standard solution. Figure 2 In the figure: 1 represents phenol; 2 represents glabridin; 3 represents licorice chalcone B; 4 represents (+)-catechin; 5 represents quercetin; 6 represents kaempferol; 7 represents naringenin; 8 represents catechol; 9 represents isorhamnetin; 10 represents 7-methoxy-2-methyl soy isoflavone; 11 represents β-sitosterol; 12 represents stigmasterol; 13 represents phloroglucinol. DETAILED DESCRIPTION
[0052] The present invention provides a method for detecting Jinliyou soft capsules, comprising the following steps:
[0053] According to the effective chemical components of the 10 traditional Chinese medicines constituting the Jinliyou soft capsule, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsule, 10 pharmacologically active ingredients of the Jinliyou soft capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, kaempferol, β-sitosterol, naringenin, isorhamnetin, stigmasterol, glabridin, licorice chalcone B, (+)-catechin and 7-methoxy-2-methyl soy isoflavones;
[0054] The Jinliyou soft capsule is extracted with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested;
[0055] Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested;
[0056] The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients;
[0057] The conditions for the high performance liquid chromatography detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is methanol; gradient elution is adopted, and the procedure of the gradient elution is:
[0058] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 94 6 8 80.4 19.6 14 71.4 28.6 20 60 40 22 60 40 23 94 6 .
[0059] In the present invention, unless otherwise specified, all preparation raw materials / components are commercially available products well known to those skilled in the art.
[0060] According to the effective chemical components of 10 traditional Chinese medicines constituting Jinliyou soft capsules, the present invention adopts a network pharmacology analysis method to obtain a compound traditional Chinese medicine network pharmacology map of Jinliyou soft capsules, and according to the compound traditional Chinese medicine network pharmacology map of Jinliyou soft capsules, 10 pharmacologically active ingredients of the Jinliyou soft capsules are obtained, and the 10 pharmacologically active ingredients are respectively quercetin, kaempferol, β-sitosterol, naringenin, isorhamnetin, stigmasterol, glabridin, licorice chalcone B, (+)-catechin and 7-methoxy-2-methyl soy isoflavones.
[0061] In the present invention, the 10 traditional Chinese medicines constituting the Jinliyou soft capsule include Radix Bupleuri, Linderae Radix, Glycyrrhiza Uralensis Fisch., Sesami Nigrum Semen., Coptis Rhizoma, Amygdalus Communis Vas, Ephedra Herba, Gentiana Macrophylla Pall, Fraxini Cortex and Aconitum Kusnezoffii Reichb.
[0062] In the present invention, the specific implementation method of obtaining the network pharmacology diagram of the compound Chinese medicine of Jinliyou soft capsule by using the network pharmacology analysis method preferably includes:
[0063] 1. Collection and screening of active ingredients
[0064] The Chinese medicine system pharmacology database analysis platform (TCMSP) was used to retrieve the effective ingredients of 10 Chinese medicines in Jinliyou soft capsules, and the possible active drug molecules were screened by using ADME parameters (the oral bioavailability threshold (OB) ≥ 30%, the drug similarity threshold (DL) ≥ 0.18%, and other parameters were set as default). The effective chemical components of Chinese medicines that could not be retrieved by TCMSP were screened by using the Chinese Medicine Integrated Pharmacology Research Platform v2.0 (TCMIP) and literature. SwissADME was used for virtual screening of drug components and the intersection with BPH gene targets was taken, and 142 effective chemical components of Jinliyou soft capsules were obtained. Among them, 12 were found in Bupleurum, 9 in Aquilaria, 87 in Licorice, 7 in Black Sesame, 10 in Coptis, 16 in Apricot, 19 in Ephedra, 2 in Gentiana Macrophylla, 3 in Cortex Fraxini, and 1 in Radix Aconitum. 15 components were common components in two or more medicinal materials.
[0065] 2. Prediction, screening and cross-validation of active ingredient target proteins
[0066] The TCMSP database was used to predict and screen the target proteins corresponding to 142 effective ingredients that met the conditions. The CTD database was used to search for related genes using prostatic hyperplasia as a keyword, and the genes with an Inference score ranking of 30 or above were intersected with the target proteins predicted by the TCMSP database, resulting in 156 intersection-related target proteins.
[0067] 3. GO functional annotation and KEGG pathway enrichment analysis
[0068] The 156 target proteins were analyzed by GO functional annotation and KEGG pathway enrichment in Metascape. GO functional annotation showed that the target genes were involved in the following processes: positive regulation of cell death, regulation of apoptosis signaling pathway, response to hormones, cell response to lipids, response to inorganic substances, response to external stimuli, etc. KEGG enrichment showed that these reaction processes may occur through pathways such as cancer pathways, lipids and atherosclerosis, chemical carcinogen-receptor activation, AGE-RAGE signaling pathway, fluid shear stress and atherosclerosis, and cell senescence.
[0069] 4. Analysis of component-target protein interaction
[0070] The 156 target proteins obtained were uploaded to the STRING database for protein-protein interaction enrichment analysis. The species was set to "Homo sapiens", free nodes were hidden, and the minimum required interaction score was set to the highest confidence (0.900) for PPI network diagram construction. Cytoscape3.9.1 was used to further analyze and optimize the PPI network diagram. A network interaction diagram consisting of 135 nodes and 647 edges was obtained (node size, color depth, and connection density represent the importance of target genes). The top 10 core genes with the highest degree values were: TP53, MAPK3, AKT1, STAT3, MAPK1, RELA, FOS, ESR1, TNF, IL6 and their interactions.
[0071] 5. Construction of network pharmacology of Jinliyou soft capsules
[0072] The corresponding genes of the 156 target proteins obtained by screening were imported into Cytoscape 3.9.1 software to draw a network diagram of Chinese medicine compound, namely the "medicine-ingredient-target" network diagram. The network has a total of 308 nodes and 2349 relationships, including 10 Jinliyou soft capsule drug nodes (Chinese medicinal materials), 156 chemical component nodes, and 237 target protein nodes. The top 10 chemical components with the highest degree values were analyzed as follows: quercetin (CAS: 117-39-5), kaempferol (CAS: 520-18-3), β-sitosterol (CAS: 83-46-5), naringenin (CAS: 480-41-1), isorhamnetin (CAS: 480-19-3), stigmasterol (CAS: 83-48-7), glabridin (CAS: 59870-68-7), licorice chalcone B (CAS: 58749-23-8), (+)-catechin (CAS: 154-23-4), and 7-methoxy-2-methyl soy isoflavone (CAS: 19725-44-1). These components are the core control components of the medicinal effect of this herbal medicine.
[0073] The present invention extracts Jinliyou soft capsules with a polar solvent, and obtains a sample to be tested after removing the solvent from the obtained extract. In the present invention, the polar solvent used for the extraction is preferably a low-carbon alcohol or a low-carbon alcohol aqueous solution, and the low-carbon alcohol preferably includes methanol or ethanol, and more preferably methanol. The low-carbon alcohol aqueous solution preferably includes a methanol aqueous solution or an ethanol aqueous solution, and more preferably an ethanol aqueous solution. The mass percentage of low-carbon alcohol in the low-carbon alcohol aqueous solution is preferably 80%. The material-liquid ratio of the Jinliyou soft capsules and the polar solvent is preferably 1: (15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions. When the extraction is carried out under heating reflux conditions, the extraction time is preferably 3-4h, and the extraction is preferably carried out in a Soxhlet extractor. When the extraction is carried out under ultrasonic conditions, the number of extractions is preferably 2 times, and the time of each extraction is preferably 30-40min. The ultrasonic conditions include: the ultrasonic power is preferably 100-150W, and the ultrasonic frequency is preferably 40-50kHz. After the extraction, an extraction liquid is obtained, and the present invention preferably separates the extraction liquid into solid and liquid to obtain an extraction liquid. The solid-liquid separation is preferably carried out by filtration. The solvent removal is preferably carried out by evaporation. The solvent removal is preferably carried out in a rotary evaporator.
[0074] After obtaining the sample to be tested, the present invention dissolves the sample to be tested in an alcohol-water solvent to obtain a sample solution. As one or more embodiments of the present invention, the sample to be tested is dissolved in an alcohol-water solvent alone to obtain a sample solution; or the sample to be tested and a marker are dissolved in an alcohol-water solvent together to obtain a sample solution, at which time the sample solution contains the sample to be tested and a marker, and the marker includes one or more of phenol, catechol and phloroglucinol, preferably phenol, catechol and phloroglucinol. In the present invention, the alcohol-water solvent for dissolving the sample to be tested is preferably a methanol aqueous solution, and the mass percentage of methanol in the methanol aqueous solution is preferably 80wt%. After the sample to be tested is dissolved in an alcohol-water solvent, an initial sample solution to be tested is obtained. The present invention preferably removes impurities from the initial sample solution to obtain the sample solution to be tested. The specific implementation of the removal of impurities is preferably membrane filtration, and the membrane filtration preferably uses a nylon membrane, and the pore size of the nylon membrane is preferably 0.22μm.
[0075] After obtaining the test sample solution, the present invention performs high performance liquid chromatography detection on the test sample solution to obtain a liquid chromatogram of the test sample solution, and obtains the peak areas corresponding to 10 pharmacologically active ingredients in the Jinliyou soft capsule from the liquid chromatogram of the test sample solution; and then obtains the mass contents of the 10 pharmacologically active ingredients in the Jinliyou soft capsule from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the 10 pharmacologically active ingredients;
[0076] The conditions for the high performance liquid chromatography detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is methanol; gradient elution is adopted, and the procedure of the gradient elution is:
[0077] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 94 6 8 80.4 19.6 14 71.4 28.6 20 60 40 22 60 40 23 94 6 .
[0078] In the present invention, the meaning of the gradient elution procedure is:
[0079] From 0 min to 8 min, the volume percentage of mobile phase B changed linearly from 6% to 19.6%;
[0080] From 8 min to 14 min, the volume percentage of mobile phase B changed linearly from 19.6% to 28.6%;
[0081] From 14 min to 20 min, the volume percentage of mobile phase B changed linearly from 28.6% to 40%;
[0082] From 20 min to 22 min, the volume percentage of mobile phase B remained constant at 40%;
[0083] From 22 min to 23 min, the volume percentage of mobile phase B changed linearly from 40% to 6%.
[0084] In the present invention, the conditions for the HPLC detection preferably include: the column temperature is preferably 30°C, the flow rate of the mobile phase is preferably 1 mL·min -1 .
[0085] In the present invention, the conditions for the HPLC detection preferably also include: the detection wavelength is preferably 278 nm.
[0086] In the present invention, in the liquid chromatography detection, the injection volume of the sample solution to be tested is preferably 10 μL.
[0087] In the present invention, the chromatographic column used in the high performance liquid chromatography is a Poroshell 120EC-C18 chromatographic column; the length of the chromatographic column is 150 mm, the inner diameter is 4.6 mm, and the size of the filler is 4 μm.
[0088] In the present invention, the method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients comprises the following steps:
[0089] Dissolving 10 pharmacologically active ingredients and a marker in an alcohol-water solvent, respectively, wherein the marker comprises one or more of phenol, catechol and phloroglucinol, respectively obtaining a series of standard solutions of the 10 pharmacologically active ingredients and the marker at different mass concentrations, respectively subjecting the 10 pharmacologically active ingredients and the marker at a series of standard solutions at different mass concentrations to high performance liquid chromatography detection, respectively obtaining a series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and the marker, and obtaining liquid chromatographic retention times and linear ranges of the 10 pharmacologically active ingredients and the marker from the series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and the marker;
[0090] A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 10 pharmacologically active ingredients, a marker and an alcohol-water solvent, wherein the marker includes one or more of phenol, catechol and phloroglucinol; a linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions and the liquid chromatographic retention times of the 10 pharmacologically active ingredients is obtained;
[0091] The linear regression equations of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution.
[0092] In the present invention, the marker is preferably phenol, catechol and phloroglucinol. When a series of standard solutions of 10 pharmacologically active ingredients and markers with different mass concentrations are subjected to HPLC detection, and a series of mixed standard solutions with different mass concentrations are subjected to HPLC detection, the HPLC detection method used is the same as the HPLC detection method of the sample solution to be tested in the above text, and will not be repeated here one by one.
[0093] In the present invention, the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution includes:
[0094] The linear regression equation of the mass concentration and peak area of the glabridin is shown in Formula 1:
[0095] y=1805.5x-11.356 Formula 1;
[0096] The linear regression equation of the mass concentration and peak area of the licorice chalcone B is shown in Formula 2:
[0097] y=27559x+5.3815Equation 2;
[0098] The linear regression equation of the mass concentration and peak area of the (+)-catechin is shown in Formula 3:
[0099] y=26758x+4.4018Equation 3;
[0100] The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 4:
[0101] y=1526.7x-5.9019 equation 4;
[0102] The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 5:
[0103] y=5903x-47.215 Formula 5;
[0104] The linear regression equation of the mass concentration and peak area of naringenin is shown in Formula 6:
[0105] y = 2902x - 20.741 Formula 6;
[0106] The linear regression equation of the mass concentration and peak area of isorhamnetin is shown in Formula 7:
[0107] y=11901x-364.91Equation 7;
[0108] The linear regression equation of the mass concentration and peak area of the 7-methoxy-2-methyl soy isoflavones is shown in Formula 8:
[0109] y=7113x-33.718 Formula 8;
[0110] The linear regression equation of the mass concentration and peak area of β-sitosterol is shown in Formula 9:
[0111] y = 12619x - 350.71 Formula 9;
[0112] The linear regression equation of the mass concentration and peak area of the stigmasterol is shown in Formula 10:
[0113] y = 18471x-608 formula 10;
[0114] In formulas 1 to 10, X represents the mass concentration of glabridin, the mass concentration of licorice chalcone B, the mass concentration of (+)-catechin, the mass concentration of quercetin, the mass concentration of kaempferol, the mass concentration of naringenin, the mass concentration of isorhamnetin, the mass concentration of 7-methoxy-2-methyl soy isoflavones, the mass concentration of β-sitosterol, and the mass concentration of stigmasterol in the mixed standard solution, respectively;
[0115] In Formulas 1 to 10, Y represents the peak area of glabridin, the peak area of licorice chalcone B, the peak area of (+)-catechin, the peak area of quercetin, the peak area of kaempferol, the peak area of naringenin, the peak area of isorhamnetin, the peak area of 7-methoxy-2-methyl soy isoflavones, the peak area of β-sitosterol, and the peak area of stigmasterol in the liquid chromatogram of the mixed standard solution, respectively.
[0116] In the present invention, the linear regression equations of mass concentrations and peak areas of the 10 pharmacologically active ingredients and 3 markers in the mixed standard solution are shown in Table 1. In Table 1, 1 represents phenol; 2 represents glabridin; 3 represents licorice chalcone B; 4 represents (+)-catechin; 5 represents quercetin; 6 represents kaempferol; 7 represents naringenin; 8 represents catechol; 9 represents isorhamnetin; 10 represents 7-methoxy-2-methyl soy isoflavones; 11 represents β-sitosterol; 12 represents stigmasterol; 13 represents phloroglucinol.
[0117] Table 1 Linear equations and linear ranges of 10 active ingredients and 3 markers
[0118] Standards Standard curve equation <![CDATA[R 2 ]]> Linear range (mg / mL) 1 y=25948x-13.671 0.9999 0.001-0.1 2 y=1805.5x-11.356 0.9992 0.005-0.5 3 y=27559x+5.3815 0.9999 0.001-0.1 4 y=26758x+4.4018 0.9999 0.001-0.1 5 y=1526.7x-5.9019 0.9999 0.005-0.5 6 y=5903x-47.215 0.9992 0.005-0.5 7 y=2902x-20.741 0.9995 0.005-0.5 8 y=23291x+4.4826 0.9998 0.001-0.1 9 y=11901x-364.91 0.9993 0.02-0.5 10 y=7113x-33.718 0.9995 0.005-0.5 11 y=12619x-350.71 0.9991 0.02-0.05 12 y=18471x-608 0.9992 0.05-0.5 13 y=13358x-598.41 0.9998 0.05-0.5
[0119] In order to further illustrate the present invention, the technical solutions provided by the present invention are described in detail below in conjunction with embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0120] Example 1
[0121] In this example, based on the effective chemical components of the 10 traditional Chinese medicines that constitute the Jinliyou soft capsules, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsules. According to the network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsules, 10 pharmacologically active ingredients of the Jinliyou soft capsules are obtained. The 10 pharmacologically active ingredients are quercetin, kaempferol, β-sitosterol, naringenin, isorhamnetin, stigmasterol, glabridin, licorice chalcone B, (+)-catechin and 7-methoxy-2-methyl soy isoflavones. Among them, the 10 traditional Chinese medicines constituting the Jinliyou soft capsule include Radix Bupleuri, Linderae Radix, Glycyrrhiza Uralensis Fisch., Sesami Nigrum Semen., Coptis Rhizoma, Amygdalus Communis Vas, Ephedra Herba, Gentiana Macrophylla Pall, Fraxini Cortex and Aconitum Kusnezoffii Reichb. In the embodiment, the specific implementation method of obtaining the network pharmacology diagram of the compound traditional Chinese medicine of Jinliyou soft capsule by using the network pharmacology analysis method includes:
[0122] 1. Collection and screening of active ingredients
[0123] The Chinese medicine system pharmacology database analysis platform (TCMSP) was used to retrieve the effective ingredients of 10 Chinese medicines in Jinliyou soft capsules, and the possible active drug molecules were screened by using ADME parameters (the oral bioavailability threshold (OB) ≥ 30%, the drug similarity threshold (DL) ≥ 0.18%, and other parameters were set as default). The effective chemical components of Chinese medicines that could not be retrieved by TCMSP were screened by using the Chinese Medicine Integrated Pharmacology Research Platform v2.0 (TCMIP) and literature. SwissADME was used for virtual screening of drug components and the intersection with BPH gene targets was taken, and 142 effective chemical components of Jinliyou soft capsules were obtained. Among them, 12 were found in Bupleurum, 9 in Aquilaria, 87 in Licorice, 7 in Black Sesame, 10 in Coptis, 16 in Apricot, 19 in Ephedra, 2 in Gentiana Macrophylla, 3 in Cortex Fraxini, and 1 in Radix Aconitum. 15 components were common components in two or more medicinal materials.
[0124] 2. Prediction, screening and cross-validation of active ingredient target proteins
[0125] The TCMSP database was used to predict and screen the target proteins corresponding to 142 effective ingredients that met the conditions. The CTD database was used to search for related genes using prostatic hyperplasia as a keyword, and the genes with an Inference score ranking of 30 or above were intersected with the target proteins predicted by the TCMSP database, resulting in 156 intersection-related target proteins.
[0126] 3. GO functional annotation and KEGG pathway enrichment analysis
[0127] The 156 target proteins were analyzed by GO functional annotation and KEGG pathway enrichment in Metascape. GO functional annotation showed that the target genes were involved in the following processes: positive regulation of cell death, regulation of apoptosis signaling pathway, response to hormones, cell response to lipids, response to inorganic substances, response to external stimuli, etc. KEGG enrichment showed that these reaction processes may occur through pathways such as cancer pathways, lipids and atherosclerosis, chemical carcinogen-receptor activation, AGE-RAGE signaling pathway, fluid shear stress and atherosclerosis, and cell senescence.
[0128] 4. Analysis of component-target protein interaction
[0129] The 156 target proteins obtained were uploaded to the STRING database for protein-protein interaction enrichment analysis. The species was set to "Homo sapiens", free nodes were hidden, and the minimum required interaction score was set to the highest confidence (0.900) for PPI network diagram construction. Cytoscape3.9.1 was used to further analyze and optimize the PPI network diagram. A network interaction diagram consisting of 135 nodes and 647 edges was obtained (node size, color depth, and connection density represent the importance of target genes). The top 10 core genes with the highest degree values were: TP53, MAPK3, AKT1, STAT3, MAPK1, RELA, FOS, ESR1, TNF, IL6 and their interactions.
[0130] 5. Construction of network pharmacology of Jinliyou soft capsules
[0131] The corresponding genes of the 156 target proteins obtained by screening were imported into Cytoscape 3.9.1 software to draw a network diagram of Chinese medicine compound, namely the "medicine-ingredient-target" network diagram. The network has a total of 308 nodes and 2349 relationships, including 10 Jinliyou soft capsule drug nodes (Chinese medicinal materials), 156 chemical component nodes, and 237 target protein nodes. The top 10 chemical components with the highest degree values were analyzed as follows: quercetin (CAS: 117-39-5), kaempferol (CAS: 520-18-3), β-sitosterol (CAS: 83-46-5), naringenin (CAS: 480-41-1), isorhamnetin (CAS: 480-19-3), stigmasterol (CAS: 83-48-7), glabridin (CAS: 59870-68-7), licorice chalcone B (CAS: 58749-23-8), (+)-catechin (CAS: 154-23-4), and 7-methoxy-2-methyl soy isoflavone (CAS: 19725-44-1). These components are the core control components of the medicinal effect of this herbal medicine.
[0132] The unique effective chemical components of the 10 Chinese medicinal materials in the Jinliyou soft capsules in this embodiment are shown in Table 2, and the common chemical components of the 10 Chinese medicinal materials in the Jinliyou soft capsules are shown in Table 3. The network pharmacology diagram of the compound Chinese medicine of the Jinliyou soft capsules obtained in this embodiment is shown in Figure 1 As shown, Figure 1 The squares are Chinese medicinal materials, the circles are ingredients, the diamonds are targets, and the hexagons are common ingredients.
[0133] Table 2 Unique effective chemical components in 10 medicinal materials of Jinliyou soft capsule
[0134]
[0135]
[0136]
[0137] Table 3 Total chemical components of 10 medicinal materials in Jinliyou soft capsule
[0138]
[0139]
[0140] Standard preparation:
[0141] Prepare individual standard solutions for the 10 active ingredients and 3 markers (phenol, catechol and phloroglucinol) of Jinliyou soft capsules: accurately weigh a certain amount of standard substance (0.1-0.5 mg), add 5 mL of 80% methanol water solvent to a 10 mL volumetric flask, fully dissolve and dilute to 10 mL to obtain a standard solution with a determined concentration. When using, 0.1 mL, 0.25 mL, 0.5 mL, 1 mL, and 2 mL of the mother solution of the standard solution can be added to a 10 mL volumetric flask, and 80% methanol water solvent can be diluted to the scale to obtain 100, 75, 50, 10, and 5 times diluted standard solutions. Liquid chromatography retention time is qualitative, and peak area-concentration linear relationship analysis is quantitative.
[0142] Preparation of mixed standard solution: Take 0.1mL of each standard substance solution of known concentration (including 10 kinds of pharmacologically active ingredient solutions and 3 kinds of marker solutions) and add them to a 10mL volumetric flask. Make up to the mark with 80% methanol-water solvent to obtain a 100-fold diluted mixed standard substance solution (the mixed standard solution can be prepared in various concentrations and proportions according to the given method. The retention time obtained by a single standard substance is slightly different from that obtained by a mixed standard substance. Therefore, the mixed standard substance spectrum is used to qualitatively and quantitatively analyze the sample). Use liquid chromatography to detect the 10 kinds of pharmacologically active ingredients in the mixed standard solution, and obtain a liquid chromatogram of the mixed standard solution, as shown in FIG. Figure 2 As shown, Figure 2 In the figure: 1 represents phenol; 2 represents glabridin; 3 represents licorice chalcone B; 4 represents (+)-catechin; 5 represents quercetin; 6 represents kaempferol; 7 represents naringenin; 8 represents catechol; 9 represents isorhamnetin; 10 represents 7-methoxy-2-methyl soy isoflavone; 11 represents β-sitosterol; 12 represents stigmasterol; 13 represents phloroglucinol.
[0143] A linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution is obtained from the mass concentration of the 10 pharmacologically active ingredients in the mixed standard solution, the liquid chromatogram of the mixed standard solution and the liquid chromatographic retention time of the 10 pharmacologically active ingredients; a linear regression equation of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution is obtained from the linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solution. Details of the linear regression equation are shown in Table 1.
[0144] 50 g of Jinliyou soft capsules (commercially available product) were added to a 1500 mL Soxhlet extractor, and an ethanol aqueous solution (wherein the mass percentage of ethanol was 80%) was added at a material-liquid mass ratio of 1:20, and the mixture was heated under reflux for 4 hours. The insoluble matter was removed by filtration, and the solvent was removed from the mixed solution by a rotary evaporator to obtain a sample to be tested.
[0145] The sample to be tested (0.1-0.5 mg) was dissolved in 10 mL of 80 wt % methanol aqueous solution and fully dissolved, and filtered through a 0.22 m nylon membrane to obtain a sample solution to be tested.
[0146] After obtaining the test sample solution, the present embodiment performs high performance liquid chromatography on the test sample solution to obtain a liquid chromatogram of the test sample solution. The peak areas corresponding to the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from the liquid chromatogram of the test sample solution; and the mass concentrations of the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentrations and peak areas of the 10 pharmacologically active ingredients.
[0147] In the embodiment, the conditions of the above-mentioned high performance liquid chromatography detection are the same, including: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1v:v% formic acid aqueous solution, and mobile phase B is methanol; gradient elution is adopted, the column temperature is preferably 30°C, and the flow rate of the mobile phase is preferably 1mL·min -1 The detection wavelength is preferably 278 nm, the injection volume of the sample solution to be tested is preferably 10 μL, and the chromatographic column used in the high performance liquid chromatography is a Poroshell 120EC-C18 chromatographic column (4 μm, 4.6×150 mm). The gradient elution procedure is:
[0148] Retention time, minutes Mobile phase A, v:v% Mobile phase B, v:v% 0 94 6 8 80.4 19.6 14 71.4 28.6 20 60 40 22 60 40 23 94 6 .
[0149] In this example, the contents of 10 core pharmacodynamic control ingredients in Jinliyou soft capsules were determined as (mg / g): glabridin (0.0018), licorice chalcone B (0.0020), (+)-catechin (0.0017), quercetin (0.0035), kaempferol (0.0032), naringenin (0.0153), isorhamnetin (0.0071), 7-methoxy-2-methyl soy isoflavones (0.0039), β-sitosterol (0.0565), and stigmasterol (0.0312).
[0150] Test Case
[0151] Activity analysis evaluation:
[0152] Preparation of Jinliyou soft capsule control: Take 10g of raw material powder, add 150mL of methanol, ultrasonic (power 100W, frequency 40kHz) for 30min, extract twice, and filter the solution under reduced pressure. Add 100mL of anhydrous ethanol to the filter residue, ultrasonically extract twice, and filter under reduced pressure. Combine the filtrate, evaporation and dry at room temperature, add 10mL of DMEM (high glucose culture medium) culture medium, and filter through a 0.22μm microporous filter membrane after ultrasonic dissolution to obtain a standard control solution, which is stored at -20℃ for use. When used, dilute with DMEM culture medium to 0.5 times, 0.25 times, and 0.1 times the concentration of the control solution.
[0153] Preparation of drug equivalent solution: Take 10 core drug control components, weigh the sample according to the content level of each substance in 10 grams of original drug, add 10mL DMEM culture medium, and filter through 0.22μm microporous membrane after ultrasonic dissolution to obtain drug equivalent solution, and store at -20℃ for use. When using, dilute with DMEM culture medium to 0.5 times, 0.25 times, and 0.1 times the concentration of drug equivalent solution.
[0154] The control solution of Jinliyou soft capsule and its pharmacodynamic equivalent solution were used to treat dihydrotestosterone-induced WPMY-1 cells. The levels of PSA, DHT and E2 in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (916 (912) ng / ml, 5.5 (5.4) nM / L, 41.9 (42.2) pM / L). The NO content and NOS activity of WPMY-1 cells were detected by kit (6.0 (5.9) UM, 0.0053 (0.0054) Ug / ml). The protein expression levels of ERα, Bax, Bcl-2 and CyclinD1 in WPMY-1 cells were detected by Western Blot (0.68 (0.67), 1.57 (1.58), 0.46 (0.45), 0.21 (0.22)). The results showed that there were no significant differences in the parameters.
[0155] WPMY-1 cells induced by dihydrotestosterone were treated with 0.5 times control and 0.5 times drug equivalent solution of Jinliyou soft capsules. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (854 (850) ng / ml, 5.1 (5.1) nM / L, 40.7 (40.4) pM / L)). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.7 (5.7) UM, 0.0046 (0.0046) Ug / ml)). The protein immunoblot (Western Blot) was used to detect the expression of ERα, Bax, Bcl-2 and Cyclin D1 proteins in WPMY-1 cells (0.72 (0.72), 1.23 (1.22), 0.57 (0.56), 0.38 (0.39)). The results showed that there was no significant difference in each parameter.
[0156] WPMY-1 cells induced by dihydrotestosterone were treated with 0.25 times control and 0.25 times drug equivalent solution of Jinliyou soft capsules. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (792 (795) ng / ml, 5.1 (5.1) nM / L, 40.6 (40.5) pM / L). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.5 (5.5) UM, 0.0042 (0.0041) Ug / ml)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 proteins in WPMY-1 cells were detected by Western Blot (0.77 (0.77), 1.05 (1.08), 0.82 (0.81), 0.75 (0.76)). The results showed that there were no significant differences in the parameters.
[0157] WPMY-1 cells induced by dihydrotestosterone were treated with 0.1 times control and 0.1 times drug equivalent solution of Jinliyou soft capsules. The PSA, DHT and E2 levels in the supernatant of WPMY-1 cells were detected by enzyme-linked immunosorbent assay (ELISA) (710 (709) ng / ml, 4.8 (4.8) nM / L, 40.3 (40.2) pM / L)). The NO content and NOS activity of WPMY-1 cells were detected by kit (5.3 (5.4) UM, 0.0039 (0.0039) Ug / ml)). The protein expression levels of ERα, Bax, Bcl-2 and Cyclin D1 proteins in WPMY-1 cells were detected by Western Blot (0.85 (0.87), 0.82 (0.81), 0.93 (0.94), 0.88 (0.89)). The results showed that there were no significant differences in the parameters.
[0158] It can be seen from the above embodiments that the detection method provided by the present invention adopts the network pharmacology analysis method to accurately determine the 10 pharmacologically active ingredients of Jinliyou soft capsules, and provides a high performance liquid chromatography detection method for the content of pharmacologically active ingredients of Jinliyou soft capsules. By controlling the detection conditions of high performance liquid chromatography, the 10 pharmacologically active ingredients of Jinliyou soft capsules can be accurately obtained, thereby being used as quality control indicators of Jinliyou soft capsules.
[0159] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. Other embodiments can be obtained based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A method for detecting Jinliyou soft capsules, It is characterized in that The following steps are involved: According to the effective chemical components of the 10 traditional Chinese medicines constituting the Jinliyou soft capsule, a network pharmacology analysis method is used to obtain a network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsule, and according to the network pharmacology map of the compound traditional Chinese medicine of the Jinliyou soft capsule, 10 pharmacologically active ingredients of the Jinliyou soft capsule are obtained, and the 10 pharmacologically active ingredients are quercetin, kaempferol, β-sitosterol, naringenin, isorhamnetin, stigmasterol, glabridin, licorice chalcone B, (+)-catechin and 7-methoxy-2-methyl soy isoflavones; The Jinliyou soft capsule is extracted with a polar solvent, and the obtained extract is desolventized to obtain a sample to be tested; Dissolving the sample to be tested in an alcohol-water solvent to obtain a sample solution to be tested; The sample solution to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the sample solution to be tested, and the peak areas corresponding to the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from the liquid chromatogram of the sample solution to be tested; and the mass contents of the 10 pharmacologically active ingredients in the Jinliyou soft capsule are obtained from a linear fitting curve or a linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients; The conditions for the HPLC detection include: the mobile phase includes mobile phase A and mobile phase B, mobile phase A is 0.1 v:v% formic acid aqueous solution, and mobile phase B is methanol; Gradient elution was used, and the procedure of the gradient elution was as follows: 。 2. The detection method according to claim 1, It is characterized in that The conditions for the HPLC detection also include: column temperature of 30°C, flow rate of the mobile phase of 1 mL min -1 .
3. The detection method according to claim 1 or 2, It is characterized in that The conditions for the high performance liquid chromatography detection also include: the detection wavelength is 278 nm.
4. The detection method according to claim 1, It is characterized in that The alcohol-water solvent for dissolving the sample to be tested is a methanol-water solution, and the mass percentage of methanol in the methanol-water solution is 80wt%.
5. The detection method according to claim 1 or 4, It is characterized in that In the liquid chromatography detection, the injection volume of the sample solution to be tested is 10 μL.
6. The detection method according to claim 1, It is characterized in that The polar solvent used for the extraction is low-carbon alcohol or low-carbon alcohol aqueous solution, the low-carbon alcohol includes methanol or ethanol, and the low-carbon alcohol aqueous solution includes methanol aqueous solution or ethanol aqueous solution; the mass percentage of low-carbon alcohol in the low-carbon alcohol aqueous solution is 80%.
7. The detection method according to claim 1 or 6, It is characterized in that The solid-liquid ratio of the Jinliyou soft capsule to the polar solvent is 1:(15-20); the extraction is carried out under heating reflux conditions or under ultrasonic conditions.
8. The detection method according to claim 1, It is characterized in that The method for obtaining the linear fitting curve and the linear regression equation of the mass concentration and peak area of the 10 pharmacologically active ingredients comprises the following steps: Dissolving 10 pharmacologically active ingredients and a marker in an alcohol-water solvent, respectively, wherein the marker comprises one or more of phenol, catechol and phloroglucinol, respectively obtaining a series of standard solutions of the 10 pharmacologically active ingredients and the marker at different mass concentrations, respectively subjecting the 10 pharmacologically active ingredients and the marker at a series of standard solutions at different mass concentrations to high performance liquid chromatography detection, respectively obtaining a series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and the marker, and obtaining liquid chromatographic retention times and linear ranges of the 10 pharmacologically active ingredients and the marker from the series of liquid chromatograms of different mass concentrations corresponding to the 10 pharmacologically active ingredients and the marker; A series of mixed standard solutions with different mass concentrations are subjected to high performance liquid chromatography to obtain liquid chromatograms of a series of mixed standard solutions with different mass concentrations, wherein the mixed standard solutions include 10 pharmacologically active ingredients, a marker and an alcohol-water solvent, wherein the marker includes one or more of phenol, catechol and phloroglucinol; a linear fitting curve of mass concentration and peak area of the 10 pharmacologically active ingredients in the mixed standard solutions with different mass concentrations, the liquid chromatograms of the mixed standard solutions and the liquid chromatographic retention times of the 10 pharmacologically active ingredients is obtained; The linear regression equations of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution were obtained from the linear fitting curves of the mass concentrations and peak areas of the 10 pharmacologically active ingredients in the mixed standard solution.
9. The detection method according to claim 1 or 8, It is characterized in that The linear regression equations of mass concentration and peak area of the 10 kinds of active ingredients in the mixed standard solution include: The linear regression equation of the mass concentration and peak area of the glabridin is shown in Formula 1: y=1805.5x-11.356 Formula 1; The linear regression equation of the mass concentration and peak area of the licorice chalcone B is shown in Formula 2: y=27559x+5.3815Equation 2; The linear regression equation of the mass concentration and peak area of the (+)-catechin is shown in Formula 3: y=26758x+4.4018Equation 3; The linear regression equation of the mass concentration and peak area of quercetin is shown in Formula 4: y=1526.7x-5.9019 equation 4; The linear regression equation of the mass concentration and peak area of kaempferol is shown in Formula 5: y=5903x-47.215 Formula 5; The linear regression equation of the mass concentration and peak area of naringenin is shown in Formula 6: y = 2902x - 20.741 Formula 6; The linear regression equation of the mass concentration and peak area of isorhamnetin is shown in Formula 7: y=11901x-364.91Equation 7; The linear regression equation of the mass concentration and peak area of the 7-methoxy-2-methyl soy isoflavones is shown in Formula 8: y=7113x-33.718 Formula 8; The linear regression equation of the mass concentration and peak area of β-sitosterol is shown in Formula 9: y = 12619x - 350.71 Formula 9; The linear regression equation of the mass concentration and peak area of the stigmasterol is shown in Formula 10: y = 18471x-608 formula 10; In formulas 1 to 10, X represents the mass concentration of glabridin, the mass concentration of licorice chalcone B, the mass concentration of (+)-catechin, the mass concentration of quercetin, the mass concentration of kaempferol, the mass concentration of naringenin, the mass concentration of isorhamnetin, the mass concentration of 7-methoxy-2-methyl soy isoflavones, the mass concentration of β-sitosterol, and the mass concentration of stigmasterol in the mixed standard solution, respectively; In Formulas 1 to 10, Y represents the peak area of glabridin, the peak area of licorice chalcone B, the peak area of (+)-catechin, the peak area of quercetin, the peak area of kaempferol, the peak area of naringenin, the peak area of isorhamnetin, the peak area of 7-methoxy-2-methyl soy isoflavones, the peak area of β-sitosterol, and the peak area of stigmasterol in the liquid chromatogram of the mixed standard solution, respectively.
10. The detection method according to claim 1, It is characterized in that The chromatographic column used in the high performance liquid chromatography is a Poroshell 120EC-C18 chromatographic column; the length of the chromatographic column is 150 mm, the inner diameter is 4.6 mm, and the size of the filler is 4 μm.
